Drug Profile
ACH 15
Alternative Names: ACH-15Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Ache Laboratories
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for phase-I development in Inflammation in Brazil (PO, Capsule)
- 03 Jun 2020 Phase I development in Inflammation is ongoing in Brazil(Ache Laboratories pipeline, June 2020)
- 03 Jun 2020 ACH 15 is available for licensing as of 03 Jun 2020. https://www.ache.com.br/